Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.39 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL342415 | 0.85 | TDP1 (0.66) | TDP1AKR1B1ALDH1A1CA1CA2 | |
| SCHEMBL14691301 | 0.83 | TDP1 (0.47) | TDP1AKR1B1ALDH1A1KMT2ACA1 | |
| SCHEMBL11072412 | 0.83 | TDP1 (0.47) | TDP1AKR1B1ALDH1A1KMT2ACA1 | |
| SCHEMBL1027463 | 0.82 | TDP1 (0.46) | TDP1AKR1B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL3730851 | 0.81 | UTS2R (0.44) | TDP1AKR1B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL11342754 | 0.79 | TP53 (0.41) | TDP1AKR1B1ALDH1A1KMT2AKEAP1 | |
| Hydrochloric Acid SCHEMBL4510368 | 0.79 | TDP1 (0.40) | TDP1AKR1B1ALDH1A1KMT2AMEN1 | |
| SCHEMBL12937502 | 0.79 | TDP1 (0.59) | TDP1AKR1B1ALDH1A1CA1CA2 | |
| SCHEMBL27812457 | 0.79 | AKR1B1 (0.49) | TDP1AKR1B1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL1028189 | 0.78 | AHCY (0.46) | TDP1AKR1B1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975707-B1 | Curable composition and planographic printing plate precursor | FUJIFILM CORP (JP) | 2017-07-19 | — | — | EP | disclosed |
| EP-1801651-B1 | Polymerizable composition and planographic printing plate precursor using the same | FUJIFILM CORP (JP) | 2017-04-19 | — | — | EP | disclosed |
| EP-1887423-B1 | Laser-decomposable resin composition and pattern-forming material using the same | FUJIFILM CORP (JP) | 2016-01-27 | — | — | EP | disclosed |
| EP-1431032-B1 | Polymerizable composition and lithographic printing plate precursor | FUJIFILM CORP (JP) | 2015-12-09 | — | — | EP | disclosed |
| EP-2039509-B1 | Curable composition, image forming material, and planographic printing plate precursor | FUJIFILM CORP (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| US-8513235-B2 | Homocysteine synthase inhibitor | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-08-20 | — | — | US | disclosed |
| EP-2486925-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-08-15 | — | — | EP | disclosed |
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-08-02 | — | — | US | disclosed |
| EP-1079972-A1 | IR-SENSITIVE COMPOSITION AND USE THEREOF FOR THE PREPARATION OF PRINTING PLATE PRECURSORS | Kodak Polychrome Graphics Company Ltd. (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000048836-A1 | IR-SENSITIVE COMPOSITION AND USE THEREOF FOR THE PREPARATION OF PRINTING PLATE PRECURSORS | KODAK POLYCHROME GRAPHICS COMPANY, LTD. (US) | 2000-08-24 | — | — | WO | disclosed |
| US-5942372-A | COMPRISED A SPECTRAL SENSITIZER THAT SENSITIZES IN THE ULTRAVIOLET OR VISIBLE REGIONS OF THE SPECTRUM AND AN N-ARYL POLYCARBOXYLIC ACID CO-INITIATOR; VERY HIGH PHOTOSPEED AND VERY GOOD SHELF-LIFE IN COMPUTER-TO-PLATE SYSTEMS | KODAK POLYCHROME GRAPHICS, LLC (US) | 1999-08-24 | — | — | US | disclosed |
| US-5914215-A | ELEMENT COMPRISING SUPPORT HAVING PHOTOIMAGEABLE, RADIATION SENSITIVE LAYER COMPRISING UNSATURATED COMPOUND, PHOTOINITIATOR SYSTEM COMPRISING SENSITIZER SENSITIZING IN ULTRAVIOLET OR VISIBLE REGION OF SPECTRUM, CO-INITIATOR | KODAK POLYCHROME GRAPHIC, LLC (US) | 1999-06-22 | — | — | US | disclosed |
| US-5888700-A | NONFOGGING, SHELF LIFE | KODAK POLYCHROME GRPAHICS, LLC (US) | 1999-03-30 | — | — | US | disclosed |
| US-5821030-A | DIRECT DIGITAL EXPOSURE; HIGH WRITING SPEED; ADHESION; ANTIFOGGING AGENTS; SHELF LIFE; USING A POLYCARBOXYLIC ACID IN THE PHOTOPOLYMERIZATION INITIATOR SYSTEM AND A BASIC COMPOUND IN THE OXYGEN BARRIER LAYER | KODAK POLYCHROME GRAPHICS (US) | 1998-10-13 | — | — | US | disclosed |
| US-5776655-A | CONTAINING PHOTOPOLYMER | EASTMAN KODAK COMPANY (US) | 1998-07-07 | — | — | US | disclosed |
| EP-0795790-A2 | Peel-developable lithographic printing plate | EASTMAN KODAK COMPANY (US) | 1997-09-17 | — | — | EP | disclosed |
| US-5629354-A | Photopolymerization initiator system comprising a spectral sensitizer and a polycarboxylic acid co-initiator | EASTMAN KODAK COMPANY (US) | 1997-05-13 | — | — | US | disclosed |
| EP-0730201-A1 | Sensitized photopolymerizable compositions and use thereof in lithographic printing plates | EASTMAN KODAK COMPANY (US) | 1996-09-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120196824-A1 | THERAPEUTIC AGENT FOR CEREBRAL INFARCTION | FABP7, TIMP3, MMP11 | TDP1 4245/4885AKR1B1 1786/4885ALDH1A1 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.